Correlation Between Molecular and Clinical Events in the Evolution of Chronic Myelocytic Leukemia to Blast Crisis
Overview
Affiliations
A patient with typical Philadelphia chromosome (Ph1)-positive chronic myelocytic leukemia (CML) was studied during sequential phases of disease: (1) initial chronic phase; (2) myeloid blast crisis; (3) second chronic phase; and (4) accelerated disease. A point mutation in the coding sequence of the p53 gene first appeared concomitantly with the blast crisis and then disappeared with the re-establishment of a second chronic phase. The chromosomal concomitant of the molecular alteration was a deletion of 17p. These observations suggest that abnormalities of the p53 anti-oncogene are temporally related to the clinical progression of some cases of CML and are probably responsible for the development of blast crisis in these cases.
Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment.
Radinsky R Cancer Metastasis Rev. 1995; 14(4):323-38.
PMID: 8821093 DOI: 10.1007/BF00690601.
p53 gene rearrangements in chronic myelocytic leukemia.
Hernandez A, Hernandez P, Corral L, Muniz A, Alaez C, Espinosa E Ann Hematol. 1993; 66(2):81-3.
PMID: 8383542 DOI: 10.1007/BF01695889.
Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H EMBO J. 1994; 13(3):504-10.
PMID: 8313895 PMC: 394839. DOI: 10.1002/j.1460-2075.1994.tb06288.x.
Sato T, Okazaki A, Okazaki M, Takahashi S, Hirata K Jpn J Cancer Res. 1995; 86(2):140-5.
PMID: 7730136 PMC: 5920757. DOI: 10.1111/j.1349-7006.1995.tb03031.x.
P53 tumor suppressor gene in chronic myelogenous leukemia: a sequential study.
Rovira A, Urbano-Ispizua A, Cervantes F, Rozman M, Vives-Corrons J, Montserrat E Ann Hematol. 1995; 70(3):129-33.
PMID: 7718641 DOI: 10.1007/BF01682032.